Skip to main content

ADVERTISEMENT

Biomarkers and GI Cancers

News
06/17/2020
Study findings suggest that MDMs in plasma are a promising method for accurately detecting distant recurrent CRC.
Study findings suggest that MDMs in plasma are a promising method for accurately detecting distant recurrent CRC.
Study findings suggest that MDMs...
06/17/2020
Oncology
Conference Insider
05/28/2020
Interim findings from the PLATFORM study do not support the use of capecitabine or durvalumab maintenance therapy vs surveillance in patients with advanced OGA.
Interim findings from the PLATFORM study do not support the use of capecitabine or durvalumab maintenance therapy vs surveillance in patients with advanced OGA.
Interim findings from the...
05/28/2020
Oncology
Conference Insider
05/28/2020
In a phase 2 study of heavily pretreated patients with advanced ASCC, pembrolizumab was active and yielded manageable toxicity, regardless of PD-L1 status.
In a phase 2 study of heavily pretreated patients with advanced ASCC, pembrolizumab was active and yielded manageable toxicity, regardless of PD-L1 status.
In a phase 2 study of heavily...
05/28/2020
Oncology
Conference Insider
05/26/2020
ctDNA is a promising, emerging biomarker to monitor treatment responses and disease progression in patients with HCC.
ctDNA is a promising, emerging biomarker to monitor treatment responses and disease progression in patients with HCC.
ctDNA is a promising, emerging...
05/26/2020
Oncology
Conference Insider
05/26/2020
Researchers posit that CHIP is an important factor in ctDNA analysis, and that the most common genes CHIP involves are DNMT3A, TET2, and TP53.
Researchers posit that CHIP is an important factor in ctDNA analysis, and that the most common genes CHIP involves are DNMT3A, TET2, and TP53.
Researchers posit that CHIP is...
05/26/2020
Oncology
Conference Insider
05/26/2020
Experts have used ctDNA concentration to detect MRD in patients with early-stage and advanced CRC, according to real-world study data.
Experts have used ctDNA concentration to detect MRD in patients with early-stage and advanced CRC, according to real-world study data.
Experts have used ctDNA...
05/26/2020
Oncology
Conference Insider
05/26/2020
ctDNA analyses conducted in patients with CRC can detect those with a high risk for recurrence with almost 100% specificity.
ctDNA analyses conducted in patients with CRC can detect those with a high risk for recurrence with almost 100% specificity.
ctDNA analyses conducted in...
05/26/2020
Oncology